STOCK TITAN

ANI Pharmaceuticals, Inc. - $ANIP STOCK NEWS

Welcome to our dedicated page for ANI Pharmaceuticals news (Ticker: $ANIP), a resource for investors and traders seeking the latest updates and insights on ANI Pharmaceuticals stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ANI Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ANI Pharmaceuticals's position in the market.

Rhea-AI Summary

ANI Pharmaceuticals announced the launch of Kionex® Suspension, a Sodium Polystyrene Sulfonate Suspension USP, for oral or rectal use. This product is the only commercially available therapeutically equivalent to the reference listed drug (RLD) SPS® Suspension. The launch highlights ANI's capability to introduce complex generics with market competition. According to President and CEO Nikhil Lalwani, this achievement demonstrates the company's strong R&D team and their ability to meet FDA's updated guidelines. The U.S. annual sales for this drug category total approximately $30.3 million, based on March 2024 IQVIA data.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
none
-
Rhea-AI Summary

ANI Pharmaceuticals reported record first quarter 2024 financial results with net revenues of $137.4 million, up 28.7% year-over-year, net income of $17.8 million, and GAAP EPS of $0.82. Rare Disease business saw significant growth with $36.9 million in net revenues. ANI reiterated 2024 guidance of $520-$542 million in net revenues, $135-$145 million in adjusted non-GAAP EBITDA, and $4.26-$4.67 in adjusted non-GAAP EPS.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.29%
Tags
-
Rhea-AI Summary

ANI Pharmaceuticals, Inc. (ANIP) announced that its CEO and CFO will participate in two upcoming healthcare conferences in New York City. The first event is Capital One 1st Annual Biotech/Biopharma Disruptors on May 14, 2024, and the second is H.C. Wainwright 2nd Annual BioConnect Conference at NASDAQ on May 20, 2024. Investors can schedule 1x1 meetings with management via provided contacts. The webcast of the events will be available on ANIP's website for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
conferences
Rhea-AI Summary
ANI Pharmaceuticals, Inc. announced its first quarter 2024 financial results discussion on May 10, 2024, at 8:30 a.m. ET. The conference call will be hosted by Nikhil Lalwani, President, and CEO, and Stephen P. Carey, CFO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
-
Rhea-AI Summary
ANI Pharmaceuticals, Inc. (ANIP) announces the launch of Baclofen Oral Suspension, a generic version of Fleqsuvy®, tapping into a $39 million market. President Nikhil Lalwani highlights ANI's market recognition and customer-centric approach.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.8%
Tags
none
-
Rhea-AI Summary
ANI Pharmaceuticals supports Sarcoidosis disease awareness during April's Sarcoidosis Awareness Month by partnering with the Foundation for Sarcoidosis Research. Sarcoidosis is a rare inflammatory disease affecting 175,000 people in the US, with higher incidence among Black Americans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
none
Rhea-AI Summary
ANI Pharmaceuticals, Inc. to host investor meetings at the Piper Sandler Spring Biopharma Symposium with CEO Nikhil Lalwani and CFO Stephen Carey on April 17, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
conferences
-
Rhea-AI Summary
ANI Pharmaceuticals, Inc. (ANIP) has announced the launch of Levofloxacin Oral Solution, a generic version of Levaquin®, aiming to tap into the $7.1 million U.S. market. The company emphasizes its commitment to growth in the Generics business and patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
none
-
Rhea-AI Summary
ANI Pharmaceuticals, Inc. (ANIP) reported strong financial results for Q4 and full year 2023, with quarterly net revenues of $131.7 million, a 39.7% YoY growth, and adjusted non-GAAP EBITDA of $30.2 million. The Rare Disease business saw significant growth, with Q4 net revenues of $41.7 million, a 40.4% QoQ increase. ANIP ended the year with $221.1 million in cash and issued a 2024 guidance with net revenues of $520 million to $542 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.26%
Tags
Rhea-AI Summary
ANI Pharmaceuticals, Inc. (ANIP) will present at the Leerink Partners Global Biopharma Conference in Miami Beach on March 12, 2024, at 2:20 p.m. ET. The webcast will be available on their website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
conferences
ANI Pharmaceuticals, Inc.

Nasdaq:ANIP

ANIP Rankings

ANIP Stock Data

1.33B
15.04M
11.2%
75.52%
0.94%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
BAUDETTE

About ANIP

ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc.